These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31626293)

  • 21. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
    Yao XY; Guan LN; Chen Q; Ren C
    Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.
    Zhu Y; Wang C; Yu M; Cui J; Liu L; Xu Z
    Protein Cell; 2013 Sep; 4(9):711-21. PubMed ID: 27023913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
    Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
    Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2.
    Connor-Robson N; Booth H; Martin JG; Gao B; Li K; Doig N; Vowles J; Browne C; Klinger L; Juhasz P; Klein C; Cowley SA; Bolam P; Hirst W; Wade-Martins R
    Neurobiol Dis; 2019 Jul; 127():512-526. PubMed ID: 30954703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional and behavioral consequences of Parkinson's disease-associated
    Benson DL; Matikainen-Ankney BA; Hussein A; Huntley GW
    Biochem Soc Trans; 2018 Dec; 46(6):1697-1705. PubMed ID: 30514770
    [No Abstract]   [Full Text] [Related]  

  • 30. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.
    Calamini B; Geyer N; Huss-Braun N; Bernhardt A; Harsany V; Rival P; Cindhuchao M; Hoffmann D; Gratzer S
    Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34114604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Petridi S; Middleton CA; Ugbode C; Fellgett A; Covill L; Elliott CJH
    G3 (Bethesda); 2020 Jun; 10(6):1903-1914. PubMed ID: 32321836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine Metabolism Pathway Is Downregulated in Dopaminergic Neurons with LRRK2 Overexpression in
    Cheng J; Wu BT; Liu HP; Lin WY
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.
    Cresto N; Gardier C; Gaillard MC; Gubinelli F; Roost P; Molina D; Josephine C; Dufour N; Auregan G; Guillermier M; Bernier S; Jan C; Gipchtein P; Hantraye P; Chartier-Harlin MC; Bonvento G; Van Camp N; Taymans JM; Cambon K; Liot G; Bemelmans AP; Brouillet E
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
    Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
    J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells.
    Panagiotakopoulou V; Ivanyuk D; De Cicco S; Haq W; Arsić A; Yu C; Messelodi D; Oldrati M; Schöndorf DC; Perez MJ; Cassatella RP; Jakobi M; Schneiderhan-Marra N; Gasser T; Nikić-Spiegel I; Deleidi M
    Nat Commun; 2020 Oct; 11(1):5163. PubMed ID: 33057020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.